276 related articles for article (PubMed ID: 25587996)
1. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
[No Abstract] [Full Text] [Related]
2. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
[TBL] [Abstract][Full Text] [Related]
3. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
Bradford PA; Huband MD; Stone GG
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735568
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.
Levasseur P; Girard AM; Claudon M; Goossens H; Black MT; Coleman K; Miossec C
Antimicrob Agents Chemother; 2012 Mar; 56(3):1606-8. PubMed ID: 22214778
[TBL] [Abstract][Full Text] [Related]
6. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
7. Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.
Torrens G; Cabot G; Ocampo-Sosa AA; Conejo MC; Zamorano L; Navarro F; Pascual Á; Martínez-Martínez L; Oliver A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6407-10. PubMed ID: 27480848
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.
Lahiri SD; Alm RA
Antimicrob Agents Chemother; 2016 May; 60(5):3183-6. PubMed ID: 26926646
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.
Buyck JM; Luyckx C; Muccioli GG; Krause KM; Nichols WW; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2017 May; 72(5):1400-1409. PubMed ID: 28137941
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
[TBL] [Abstract][Full Text] [Related]
13. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
Lahiri SD; Walkup GK; Whiteaker JD; Palmer T; McCormack K; Tanudra MA; Nash TJ; Thresher J; Johnstone MR; Hajec L; Livchak S; McLaughlin RE; Alm RA
J Antimicrob Chemother; 2015; 70(6):1650-8. PubMed ID: 25645206
[TBL] [Abstract][Full Text] [Related]
14. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
Jones RN; Holliday NM; Krause KM
Antimicrob Agents Chemother; 2015 Aug; 59(8):5036-9. PubMed ID: 26014937
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Keepers TR; Gomez M; Celeri C; Nichols WW; Krause KM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5297-305. PubMed ID: 24957838
[TBL] [Abstract][Full Text] [Related]
16. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
18. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
[TBL] [Abstract][Full Text] [Related]
19.
Fraile-Ribot PA; Mulet X; Cabot G; Del Barrio-Tofiño E; Juan C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674059
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
